Suppr超能文献

骨生物制剂在骨质疏松性骨折治疗中的应用。

Use of osteobiologics in the management of osteoporotic fractures.

机构信息

St. Michael's Hospital, 55 Queen St. East, Suite 800, Toronto, Ontario M5C1R6, Canada.

出版信息

J Orthop Trauma. 2011 Jun;25 Suppl 2:S51-5. doi: 10.1097/BOT.0b013e31821b8c52.

Abstract

Osteoporotic fractures present a number of significant challenges for surgical management, including high degrees of fracture comminution, poor implant fixation secondary to inferior bone quality, and compromised capacity for fracture healing. Osteobiologics are materials/agents that can promote fracture healing and enhance fracture stability. Given the challenges presented by osteoporotic fractures, they seem ideally suited to potentially benefit from the application of osteobiologics. Despite this, limited clinical investigation into the use of osteobiologics in the management of osteoporotic fractures has been performed. This article reviews a select number of osteobiologic products and the evidence for their use in osteoporotic fractures.

摘要

骨质疏松性骨折的手术治疗存在诸多挑战,包括骨折严重粉碎、骨质量差导致植入物固定不佳,以及骨折愈合能力受损。骨生物材料是能够促进骨折愈合和增强骨折稳定性的材料/药物。鉴于骨质疏松性骨折带来的挑战,它们似乎非常适合从骨生物材料的应用中获益。尽管如此,在骨质疏松性骨折的治疗中应用骨生物材料的临床研究非常有限。本文回顾了一些骨生物材料产品,并探讨了它们在骨质疏松性骨折中的应用证据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验